Cargando…

Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ

PI3K-δ and PI3K-γ are critical regulators of T-cell differentiation, senescence, and metabolism. PI3K-δ and PI3K-γ signaling can contribute to T-cell inhibition via intrinsic mechanisms and regulation of suppressor cell populations, including regulatory T-cells and myeloid derived suppressor cells i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chandrasekaran, Sanjay, Funk, Christopher Ronald, Kleber, Troy, Paulos, Chrystal M., Shanmugam, Mala, Waller, Edmund K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427697/
https://www.ncbi.nlm.nih.gov/pubmed/34512641
http://dx.doi.org/10.3389/fimmu.2021.718621
_version_ 1783750230072623104
author Chandrasekaran, Sanjay
Funk, Christopher Ronald
Kleber, Troy
Paulos, Chrystal M.
Shanmugam, Mala
Waller, Edmund K.
author_facet Chandrasekaran, Sanjay
Funk, Christopher Ronald
Kleber, Troy
Paulos, Chrystal M.
Shanmugam, Mala
Waller, Edmund K.
author_sort Chandrasekaran, Sanjay
collection PubMed
description PI3K-δ and PI3K-γ are critical regulators of T-cell differentiation, senescence, and metabolism. PI3K-δ and PI3K-γ signaling can contribute to T-cell inhibition via intrinsic mechanisms and regulation of suppressor cell populations, including regulatory T-cells and myeloid derived suppressor cells in the tumor. We examine an exciting new role for using selective inhibitors of the PI3K δ- and γ-isoforms as modulators of T-cell phenotype and function in immunotherapy. Herein we review the current literature on the implications of PI3K-δ and -γ inhibition in T-cell biology, discuss existing challenges in adoptive T-cell therapies and checkpoint blockade inhibitors, and highlight ongoing efforts and future directions to incorporate PI3K-δ and PI3K-γ as synergistic T-cell modulators in immunotherapy.
format Online
Article
Text
id pubmed-8427697
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84276972021-09-10 Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ Chandrasekaran, Sanjay Funk, Christopher Ronald Kleber, Troy Paulos, Chrystal M. Shanmugam, Mala Waller, Edmund K. Front Immunol Immunology PI3K-δ and PI3K-γ are critical regulators of T-cell differentiation, senescence, and metabolism. PI3K-δ and PI3K-γ signaling can contribute to T-cell inhibition via intrinsic mechanisms and regulation of suppressor cell populations, including regulatory T-cells and myeloid derived suppressor cells in the tumor. We examine an exciting new role for using selective inhibitors of the PI3K δ- and γ-isoforms as modulators of T-cell phenotype and function in immunotherapy. Herein we review the current literature on the implications of PI3K-δ and -γ inhibition in T-cell biology, discuss existing challenges in adoptive T-cell therapies and checkpoint blockade inhibitors, and highlight ongoing efforts and future directions to incorporate PI3K-δ and PI3K-γ as synergistic T-cell modulators in immunotherapy. Frontiers Media S.A. 2021-08-26 /pmc/articles/PMC8427697/ /pubmed/34512641 http://dx.doi.org/10.3389/fimmu.2021.718621 Text en Copyright © 2021 Chandrasekaran, Funk, Kleber, Paulos, Shanmugam and Waller https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Chandrasekaran, Sanjay
Funk, Christopher Ronald
Kleber, Troy
Paulos, Chrystal M.
Shanmugam, Mala
Waller, Edmund K.
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
title Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
title_full Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
title_fullStr Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
title_full_unstemmed Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
title_short Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
title_sort strategies to overcome failures in t-cell immunotherapies by targeting pi3k-δ and –γ
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8427697/
https://www.ncbi.nlm.nih.gov/pubmed/34512641
http://dx.doi.org/10.3389/fimmu.2021.718621
work_keys_str_mv AT chandrasekaransanjay strategiestoovercomefailuresintcellimmunotherapiesbytargetingpi3kdandg
AT funkchristopherronald strategiestoovercomefailuresintcellimmunotherapiesbytargetingpi3kdandg
AT klebertroy strategiestoovercomefailuresintcellimmunotherapiesbytargetingpi3kdandg
AT pauloschrystalm strategiestoovercomefailuresintcellimmunotherapiesbytargetingpi3kdandg
AT shanmugammala strategiestoovercomefailuresintcellimmunotherapiesbytargetingpi3kdandg
AT walleredmundk strategiestoovercomefailuresintcellimmunotherapiesbytargetingpi3kdandg